Peter Heerma Sells 3,074 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) insider Peter Heerma sold 3,074 shares of the stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $25.00, for a total transaction of $76,850.00. Following the completion of the transaction, the insider now owns 127,634 shares in the company, valued at approximately $3,190,850. This trade represents a 2.35 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Peter Heerma also recently made the following trade(s):

• On Wednesday, January 22nd, Peter Heerma sold 1,584 shares of Travere Therapeutics stock. The stock was sold at an average price of $18.94, for a total transaction of $30,000.96.

Travere Therapeutics Trading Up 2.2 %

Shares of NASDAQ:TVTX opened at $23.72 on Friday. Travere Therapeutics, Inc. has a 1 year low of $5.12 and a 1 year high of $25.29. The firm has a market capitalization of $1.85 billion, a price-to-earnings ratio of -5.21 and a beta of 0.72. The company has a debt-to-equity ratio of 24.96, a current ratio of 1.71 and a quick ratio of 1.68. The business’s 50 day moving average price is $19.14 and its 200-day moving average price is $16.01.

Analysts Set New Price Targets

TVTX has been the topic of a number of analyst reports. Cantor Fitzgerald initiated coverage on shares of Travere Therapeutics in a research note on Friday, January 10th. They set an “overweight” rating on the stock. HC Wainwright raised their price objective on shares of Travere Therapeutics from $18.00 to $22.00 and gave the stock a “buy” rating in a research note on Wednesday, January 15th. Evercore ISI raised their price objective on shares of Travere Therapeutics from $33.00 to $45.00 and gave the stock an “outperform” rating in a research note on Wednesday. Piper Sandler raised their price objective on shares of Travere Therapeutics from $12.00 to $22.00 and gave the stock a “neutral” rating in a research note on Thursday, November 14th. Finally, Scotiabank raised their price objective on shares of Travere Therapeutics from $27.00 to $32.00 and gave the stock a “sector outperform” rating in a research note on Wednesday. One investment analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat.com, Travere Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $27.77.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC lifted its holdings in Travere Therapeutics by 28.5% in the 4th quarter. Renaissance Technologies LLC now owns 2,409,514 shares of the company’s stock valued at $41,974,000 after purchasing an additional 534,500 shares in the last quarter. Emerald Advisers LLC lifted its holdings in Travere Therapeutics by 8.4% in the 4th quarter. Emerald Advisers LLC now owns 2,125,744 shares of the company’s stock valued at $37,030,000 after purchasing an additional 165,085 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Travere Therapeutics by 6.4% in the 4th quarter. Geode Capital Management LLC now owns 1,842,301 shares of the company’s stock valued at $32,100,000 after purchasing an additional 111,256 shares in the last quarter. Finepoint Capital LP lifted its holdings in Travere Therapeutics by 0.3% in the 3rd quarter. Finepoint Capital LP now owns 1,782,267 shares of the company’s stock valued at $24,934,000 after purchasing an additional 5,539 shares in the last quarter. Finally, Emerald Mutual Fund Advisers Trust lifted its holdings in Travere Therapeutics by 26.0% in the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 1,185,709 shares of the company’s stock valued at $16,588,000 after purchasing an additional 244,444 shares in the last quarter.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.